ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.
H.C. Wainwright Liver Disease Virtual Conference – October 21-22, 2025
Presentation available on demand beginning October 21 at 7:00 am ET and virtual 1x1s on October 22
Aniz Girach, MD, Chief Medical Officer, and Paul Yang, MD, PhD, Casey Eye Institute will discuss which vision measures are most informative in Usher syndrome, the role of baseline and disease progression, and objectives of the Stellar trial.
ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company strategy. Management to host a conference call today at 8:00am EDT (14:00 CET).
This presentation reviews Axiomer editing oligonucleotides (EONs) structure activity, the potential of Axiomer platform as well as its applicability for the treatment of liver originated disorders.
ProQR will present new preclinical data for Axiomer, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the ASGCT Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.
